Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc., as indicated in the metadata) on April 28, 2023, regarding an event that occurred on April 26, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol ACRX.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the receipt of a written notice from the Nasdaq Stock Market, LLC stating that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1). The deficiency is due to the Company's common stock failing to maintain a minimum bid price of $1.00 per share for a period of 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted 180 calendar days (until October 23, 2023) to regain compliance.
- Requirement to Cure: To maintain listing, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Secondary Compliance Option: If the Company fails to regain compliance within the initial 180 days, it may be eligible for an additional 180-day period if it meets other listing standards (such as market value of publicly held shares) and intends to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: If the Company cannot cure the deficiency or is deemed ineligible for an extension, Nasdaq will issue a notice that the common stock will be subject to delisting.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of AcelRx Pharmaceuticals, Inc. (ACRX) to assess proximity to the $1.00 threshold.
- Monitor future press releases or filings for announcements regarding a potential reverse stock split.
- Check the Nasdaq website for any updates on the Company's compliance status or extension eligibility.
- Review the Company's most recent 10-Q or 10-K for financial health metrics, as this 8-K contains no financial data.